Drug shortages dominate 2011 headlines

Ask average consumers to identify the biggest trend in pharmaceuticals, and they'd likely come back with one word: Shortages. Supply problems affected everything from oncology drugs to anesthetics. The former made headlines because hundreds of cancer patients had their treatments delayed or revamped. The latter, because U.S. death-penalty states couldn't get the drugs used in executions.

More drugs ran short in 2011 than ever before, thanks to a variety of manufacturing problems and financial challenges. Drug plants ran afoul of FDA manufacturing practices, hampering production. The number of suppliers for certain low-margin generics dwindled, sometimes to a single manufacturer. Raw materials for some drug ingredients ran short. Rival drugmakers tried to ramp up output to fill the supply gaps, but couldn't boost production overnight.

The shortages grew so acute—and so public—that President Obama signed an executive order demanding that the FDA, in effect, "do something." Lawmakers proposed new rules. The Government Accountability Office concluded that the only way to address drug scarcity would be to give the FDA more power. The agency could then require drugmakers to raise red flags when they hit snags that could result in shortages—and to demand action to prevent potential shortages or fix existing ones. Whether Congress would actually grant such powers is another question.

Special Report: Top drug shortages by treatment category

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.